Two New Professors at CITCO
CITCO is strengthened by the appointment of two professors in Hematology Department X. Chief Physician, Ph.D. Thomas Stauffer Larsen, leads the CAR-T cell program in the department and clinical research in the field of lymphoma, while Chief Physician, Ph.D. Henrik Frederiksen becomes head of research and joins CITCO's management team. Both play key roles in CITCO's success in implementing CAR-T cell therapy at OUH. Both professorships are affiliated with the Research Unit for Hematology at the Clinical Institute of the University of Southern Denmark.
Professor Thomas Stauffer Larsen
Thomas Stauffer Larsen has been appointed as a professor in the Department of Hematology at OUH. He graduated as a physician from SDU in 2001 and earned his Ph.D. in 2008. Since obtaining his specialist certification in 2013, he has focused on lymphomas, particularly aggressive B-cell lymphomas. In 2013, he became a chief physician in the Hematology Department at OUH, and since 2016, as a senior chief physician, he has been clinically responsible for patients with lymphatic cancer. During this period, clinical research activity in the area has increased significantly.
Thomas Stauffer Larsen has been one of the pioneers behind establishing OUH as a CAR T-cell treatment center and, together with Professor Torben Barington from the Department of Clinical Immunology, has led the establishment of CITCO. As a professor, Thomas Stauffer Larsen will continue his work in research and development of lymphoma treatments, including introducing new advanced forms of cellular therapy.
Professor Henrik Frederiksen
Henrik Frederiksen has been appointed as a professor and research leader in the Department of Hematology. Since 2018, he has held a time-limited professorship at the same department with a smaller area of responsibility. He is also joining the management team at CITCO.
His primary research areas are classical (non-malignant) hematological diseases and the complications and reduced quality of life that aging, frailty, and diagnoses with other chronic diseases bring to patients with hematological cancer. He was the chairman of the Danish Society of Hematology from 2017 to 2022 and has since chaired the professional committee of the Danish Comprehensive Cancer Center. He has played a significant role in national efforts to develop cellular immunotherapy and establish the Danish CAR-T Cell Network (DCTN).